Glory Adebayo

Ms. Glory Adebayo


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GAGlory Adebayo
Glory Adebayo
IAIsaac Ayanda
Isaac Ayanda
MRMatthias Rottmann
Matthias Rottmann
OAOlusola S. Ajibaye
Olusola S. Ajibaye
Gbolahan Oladipupo OduseluGbolahan Oladipupo Oduselu
Gbolahan Oladipupo Oduselu
EAEzekiel Adebiyi
Ezekiel Adebiyi
New chemical entities are constantly being investigated towards antimalarial drug discovery, and they require animal models for toxicity and efficacy testing. Murine models show physiological similarities to humans and are therefore indispensable in the search for novel antimalarial drugs. They provide a preclinical basis (following in vitro assessments of newly identified lead compounds) for further assessment in the drug development pipeline. Specific mouse strains, non-humanized and humanized, have successfully been infected with rodent Plasmodium species and the human Plasmodium species, respectively. Infected mice provide a platform for the assessment of treatment options being sought. In vivo pharmacokinetic evaluations are necessary when determining the fate of potential antimalarials in addition to the efficacy assessment of these chemical entities. This review describes the role of murine models in the drug development pipeline. It also explains some in vivo pharmacokinetic, safety, and efficacy parameters necessary for making appropriate choices of lead compounds in antimalarial drug discovery. Despite the advantages of murine models in antimalarial drug discovery, certain limitations are also highlighted.

23 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
GAGlory Adebayo
Glory Adebayo
IAIsaac Ayanda
Isaac Ayanda
Gbolahan Oladipupo OduseluGbolahan Oladipupo Oduselu
Gbolahan Oladipupo Oduselu
OAOlusola Ajibaye
Olusola Ajibaye
GOGbolahan Oduselu
Gbolahan Oduselu
EAEzekiel Adebiyi
Ezekiel Adebiyi
New chemical entities are consistently being investigated in antimalarial drug discovery and they require animal models for toxicity and efficacy testing. Murine models in searching for novel antimalarial drugs are inevitable because they show unique similarities to human physiology during malaria pathogenesis. Therefore, they provide a preclinical basis (following in vitro assessments of newly identified lead compounds) for further assessment in the drug development pipeline. Specific mouse strains, non-humanized and humanized, have successfully been infected with rodent Plasmodium species and the human Plasmodium falciparum respectively. Infected mice provide a platform for the assessment of treatment options being sought. In vivo pharmacokinetic evaluations are necessary when determining the fate of new lead compounds in addition to the efficacy assessment of these chemical entities. This review highlights specific murine models important for antimalarial drug discovery and their resultant critical in vivo pharmacokinetic, safety, and efficacy assessments necessary for making appropriate choices of lead compounds.